secwatch.observer — SEC 8-K summary
======================================

Issuer:     XOMA Royalty Corp (XOMA)
CIK:        0000791908
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001193125-23-271925
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

XOMA reports Q3 net loss of $5.5M, highlights NDA filings and $5M milestone from Day One
--------------------------------------------------------------------------------

- Q3 revenues $0.8M vs $0.5M YoY; net loss $5.5M vs $4.2M YoY.
- G&A expenses $6.4M including $2.7M non-cash stock comp; net cash used in ops $2.1M.
- Received $6.6M in royalty & milestone payments; ended Q3 with $33.5M cash.
- Subsequent: earned $5M milestone from Day One on FDA acceptance of tovorafenib NDA; PDUFA April 30, 2024.
- Organon terminated license for ebopiprant; XOMA to seek out-licensing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/791908/000119312523271925/0001193125-23-271925-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/791908/000119312523271925/d893832d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-271925

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer